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The Anti-Oxidative Capacity of High-Density Lipoprotein
Is Reduced in Acute Coronary Syndrome
But Not in Stable Coronary Artery Disease
Parin J. Patel, MD,*† Amit V. Khera, MD,†‡§ Kashif Jafri, BA,† Robert L. Wilensky, MD,*‡
Daniel J. Rader, MD*†‡§
Philadelphia, Pennsylvania
Objectives This study examined an anti-inflammatory property of high-density lipoprotein (HDL) in subjects with acute coro-
nary syndrome (ACS) and stable coronary artery disease (CAD) compared with control subjects.
Background HDL has anti-inflammatory properties in vitro, but its relationship to coronary disease in humans is unclear. The
high-density lipoprotein inflammatory index (HII) measures the ability of HDL to mitigate oxidation of low-density
lipoprotein; this function may be impaired in ACS and/or CAD.
Methods We measured HII in 193 patients undergoing angiography for symptoms of CAD. Control subjects (n  99) had
no angiographic CAD, chronic CAD subjects (n  51) had 70% vessel stenosis, and ACS subjects (n  43) had
20% vessel stenosis and ischemia or infarction. We also examined HII in a cohort of healthy subjects randomly
assigned to a statin or placebo.
Results Subjects who had ACS had higher HII (less antioxidative capacity) compared with controls (1.57 vs. 1.17, p 
0.005) or those with chronic CAD (1.57 vs. 1.11, p  0.006). HII was not different in subjects with stable CAD
compared with controls. Furthermore, those subjects with higher HII were more likely to have ACS than no CAD
(quartile 4 vs. 1, odds ratio [OR]: 1.74, p  0.008). In a multivariate logistic regression model, HII was associ-
ated with ACS after adjusting for traditional cardiac risk factors (OR: 3.8, p  0.003). There was a small im-
provement in HII after statin therapy compared with placebo (14%, p  0.03).
Conclusions HDL has less anti-inflammatory capacity as assessed by HII in the setting of ACS compared with controls or sub-
jects with chronic CAD. (J Am Coll Cardiol 2011;58:2068–75) © 2011 by the American College of Cardiology
Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.08.030r
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wThe Framingham Heart Study and numerous confirmatory
studies have demonstrated a strong inverse correlation between
high-density lipoprotein (HDL) level and cardiovascular dis-
ease risk (1,2). Despite aggressive lowering of low-density
lipoprotein (LDL), low HDL remains a significant cardiovas-
cular risk factor in high-risk patients (3). Furthermore, the
ost recent trial of cholesteryl ester transfer protein inhibition
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accepted August 2, 2011.aised HDL levels by more than 70% but resulted in significant
arm (4). Additionally, mutations in HDL metabolism or
tructure result in varying levels of HDL that do not correlate
ith atherosclerotic risk as predicted by Framingham (5–7),
nd modifications to HDL that occur in various disease states
eem to attenuate its atheroprotective effect (8–10).
HDL facilitates the efflux of cholesterol from cells such as
acrophages, promoting reverse cholesterol transport. A
ecent study showed that cholesterol efflux capacity, or the
bility of HDL to promote reverse cholesterol transport
rom macrophages, correlated with atherosclerosis, inde-
endent of HDL mass (11). Numerous additional functions
ave been ascribed to HDL, including roles in countering
nflammation, oxidation, platelet activation, and promoting
ndothelial health (8). Many cell-based assays have been
eveloped to measure HDL function, but the high-density
ipoprotein inflammatory index (HII) is a measure of how
ell HDL can prevent the oxidation of LDL in a cell-freenvironment (12). A few, mostly small, studies have sug-
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November 8, 2011:2068–75 HDL Anti-Inflammatory Property Is Impaired in ACSgested that patients with underlying inflammatory condi-
tions tend to have HDL that has less anti-inflammatory
capacity as measured by the HII (12–20).
Patients with acute coronary syndrome (ACS) have
flow-limiting lesions in the coronary arteries. But ACS
constitutes a uniquely inflammatory milieu; for example, the
proinflammatory cytokine CXCL16 is more highly ex-
pressed in subjects with acute myocardial infarction than
those with chronic atherosclerosis (21). Given that even
small changes in the microenvironment can alter HDL
structure and function (22,23), we hypothesized that HDL
has impaired anti-inflammatory capacity in patients with
ACS, but not in those with stable CAD, as measured by the
ability of HDL to prevent oxidation of LDL.
Methods
Study population. The PennCATH (University of Pennsyl-
vania Catheterization) study examined associations between
biochemical and genetic markers in predominantly white
patients undergoing catheterization to evaluate coronary anat-
omy (11,24,25). The study is institutional review board ap-
proved (Hospital of the University of Pennsylvania), and all
subjects have provided written consent. We selected a new
3-arm, nested case-control sample from this population in a
manner previously described (21). Briefly, 193 patients were
chosen: 1) control subjects (n  99) with no angiographic
coronary artery disease (CAD); 2) chronic CAD cases (n 51,
1 vessel with70% stenosis); and 3) ACS cases (n 43, any
essel with 20% stenosis in the setting of elevated cardiac
nzymes (creatinine kinase [CK] and CK-MB, troponin I, or
roponin T) and/or dynamic electrocardiogram changes). This
ested case-control study included a case/control ratio of 1:2,
ith cases being either ACS or chronic CAD compared with
ontrol subjects. Subjects were selected consecutively from the
edian enrollment period, and the conductors of the HII assay
ere blinded to group assignment.
HII was additionally tested in available samples from sub-
ects who were enrolled in a previously reported trial of statin
herapy (26). Briefly, 99 subjects with high-normal cholesterol
evels (LDL 130 to 220 mg/dl) but otherwise healthy, on no
ipid-lowering therapies, were randomized to placebo (n 24),
ravastatin 40 mg daily (n  23), atorvastatin 10 mg daily (n
27), or atorvastatin 80 mg daily (n  24). Serum was
ollected prior to treatment and after 16 weeks of therapy.
easurement of HDL anti-inflammatory function. HII
easures the ability of apolipoprotein (apo)B-depleted serum to
nhibit or enhance the oxidation of LDL in the presence of a
uorescent organic substrate. The assay was performed essentially
s previously described (12). After polyethylene glycol precipita-
ion of apo B, HDL containing supernatant was used in the assay
Online Fig. 1). We directly measured HDL concentration and
ontrolled for it with post hoc analysis. Additionally, pooled
urified LDL was obtained from the Core Lipid Laboratory at
he Children’s Hospital of Philadelphia (Philadelphia, Pennsylva-
ia); to optimize the redox reaction, LDL was then oxidized ty CuSO4 dialysis (27). Oxi-
ized LDL was then dialyzed
gain in phosphate-buffered sa-
ine (PBS) and diluted in PBS to
nal concentration of 100 g/ml
rior to use as described (12).
The organic phospholipid 2=,7=-
ichlorodihydrofluorescein diacetate
DCF) fluoresces when oxidized
nd exposed to light. This substrate
as prepared as described previously
12). Oxidized LDL (final concen-
ration: 1.4g/ml), DCF (final con-
centration: 2.9 g/ml), and a fixed
volume of apo B–depleted serum
from study subjects (5 l) were in-
ubated with PBS to a final volume
f 175 l in individual wells of a
6-well round-bottom polypropyl-
ne microtiter plate (Fisher Scien-
ific, Pittsburgh, Pennsylvania). The
late was incubated at 37°C in a
icroplate reader (Spectra Max, Gemini XS, Molecular De-
ices, Sunnyvale, California). Serial excitations at 485 nm were
erformed every 90 s, accompanied by automated plate shak-
ng. Fluorescence at emission wavelength of 530 nm and cutoff
f 515 nm was measured after 1 h of incubation. Samples were
lated in duplicate, and mean fluorescence recorded. The mean
ntra-assay coefficient of variation for all samples was 4.1%.
HII was calculated by the following formula: optical density
f DCF incubated with apo B–depleted serum minus the
ptical density of DCF incubated alone. To correct for inter-
ssay variability across different plates, a pooled serum control
rom 3 healthy volunteers was included on each plate, and
alues for samples from subjects in the study were normalized
y this pooled value. Additional tests performed to validate the
easurement of the HDL inflammatory index are described in
he Online Appendix (Online Figs. 2 and 3).
ther biochemical and clinical markers. We examined
he association of HII with other markers of HDL function
nd clinical or biochemical markers of atherosclerosis. HDL-
ediated cholesterol efflux capacity was calculated as previously
escribed, and primary data were re-analyzed in this study (11).
he atherogenic index of plasma (AIP) is the logarithmic
ransformation of the ratio of plasma triglyceride (TG) level to
DL level. This measure correlates with angiographic CAD
n a population of subjects at risk for atherosclerosis (28). We
alculated AIP log([TG]/[HDL]) for our study population.
tatistical analysis. Results are expressed as mean and SD
or continuous variables, or median and interquartile range if
ata were skewed. HII and TG level showed a non-normal
istribution in our population, similar to previous findings
28); this corrected after logarithmic transformation, which
as used in all subsequent analyses (Online Fig. 4). Study
roups were compared using analysis of variance and Student t
Abbreviations
and Acronyms
ACS  acute coronary
syndrome(s)
AIP  atherogenic index of
plasma
apo  apolipoprotein
BMI  body mass index
CAD  coronary artery
disease
CI  confidence interval
HDL  high-density
lipoprotein
HII  high-density
lipoprotein inflammatory
index
LDL  low-density
lipoprotein
OR  odds ratio
TG  triglyceridesest, and the association of HII with clinical variables was
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HDL Anti-Inflammatory Property Is Impaired in ACS November 8, 2011:2068–75assessed with the use of Pearson’s correlation coefficients.
Chi-square or Fisher exact test was employed for comparisons
between nominal variables. For non-Gaussian data, nonpara-
metric tests were employed, including Wilcoxon/Kruskal-
Wallis rank sum tests and Van der Waerden test for group
differences, and Spearman rank correlation coefficients for
linear correlations. Multinomial logistic regression was used to
examine the association between HII and coronary artery
disease status after adjustment for age, sex, smoking status,
diabetes, hypertension, cholesterol level, triglyceride level,
LDL level, and HDL mass. Significant p values were 0.05
n 2-tailed analysis. Analysis of HII and other variables before
Figure 1 Association of HII With Traditional Cardiac Risk Facto
On bivariate analysis, body mass index (BMI) (A), high-density lipoprotein (HDL) co
log[TG/HDL]) (D) all correlated significantly with high-density lipoprotein inflammat
not correlate with HII. Values for HII and triglyceride level were logarithmically trannd after statin treatment was performed using matched pairs
tests. Data were analyzed using JMP 8.0 statistical software
SAS Institute, Cary, North Carolina).
esults
ssociation of HII with traditional cardiac risk factors.
e examined the relationship between HII and traditional
ardiac risk factors in this cohort of high-risk patients (Fig. 1). Sex,
ge, smoking status, diabetes status, hypertension status, total
holesterol, and LDL concentration did not correlate with HII
p  0.05). However, HDL concentration was inversely
ration (B), triglyceride (TG) level (C), and atherogenic index of plasma (AIP,
ex (HII). HDL-mediated cholesterol efflux capacity (percent average efflux) (E) did
d to achieve a normal distribution prior to analysis.rs
ncent
ory ind
sforme
h-dens
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November 8, 2011:2068–75 HDL Anti-Inflammatory Property Is Impaired in ACScorrelated with HII, as expected (p  0.003). Additionally,
body mass index (BMI) and TG correlated positively with HII
(p  0.003 and p  0.001, respectively). HII and AIP, which
incorporates both HDL and TG concentration, also correlated
positively (p  0.001). HII did not correlate with cholesterol
efflux capacity.
Correlation of HII with CAD. The baseline characteris-
tics of the case-control cohort are presented in Table 1.
Distribution of HII in the study population is shown in
Online Figure 4.
After log transformation of HII values, subjects with ACS
had significantly higher average HII than control subjects,
despite having no difference in average HDL cholesterol (Fig. 2).
Mean HII for acute CAD subjects was 1.57 1.15, and mean
HII for control subjects was 1.17  0.58 (p  0.005; Online
Fig. 5). There was no difference between mean HII in chronic
Baseline Clinical Characteristics of CAD SubjecTable 1 Baseline Clinical Characteristics of
Control
(n  99)
Male 59 (60%)
Age, yrs 61.8 10.2
BMI, kg/m2 28.3 5.8
Smokers 43 (45%)
Diabetic patients 10 (10%)
Hypertensive patients 48 (49%)
Log(triglycerides) 4.77 (4.62–4.93)
Total cholesterol, mg/dl 174 37
HDL, mg/dl 46 15
LDL, mg/dl 103 30
Values are density (%), mean  SD, or mean (95% confidence interva
2-tailed Student t test, chronic CAD compared with control. ‡There wa
(p  0.11) or the control and ACS subjects (p  0.15).
BMI  body mass index; CAD  coronary artery disease; HDL  hig
Figure 2 Mean HII Is Different Among Cases and Controls
The high-density lipoprotein inflammatory index (HII) was measured in 99 control
subjects, 51 chronic coronary artery disease (CAD) subjects, and 43 subjects with
angiographic CAD and either dynamic electrocardiogram changes or elevation of
cardiac enzymes. Data are presented here after log transformation of HII (for non-
parametric results, see Online Fig. 5). Error bars represent the standard error of
the mean. There was no significant difference between mean HII in control sub-
jects and those with chronic CAD. *p  0.005, t test comparison of individual
means, acute coronary syndrome (ACS) versus control.CAD subjects (1.11  0.70) and control subjects (p  0.6).
However, there was a significant difference between ACS
subjects and chronic CAD subjects (p 0.006). Furthermore,
these results persisted after controlling for HDL concentration
(acute vs. control, p 0.02; acute vs. chronic, p 0.03; control
vs. chronic, p  0.6). Results were not different upon non-
parametric analysis using non–log-transformed values for HII
(Online Fig. 5).
The proportion of subjects with ACS increases as HII
increases (Fig. 3). In the multivariate logistic regression model,
higher HII was associated with an increased risk of ACS
compared with control subjects (odds ratio [OR] per 1 SD
increase in HII was 3.8 [95% confidence interval (CI): 3.35 to
4.25]; p  0.003). Additionally, subjects with higher HII had
an increased risk of having ACS compared with having chronic
CAD (OR: 4.8 [95% CI: 4.3 to 5.2]; p 0.002). Comparison
of chronic CAD subjects with controls revealed only age as a
predictive risk factor (OR: 0.94 [95% CI: 0.92 to 0.96]; p 
0.005). Higher age was not significantly predictive of chronic
CAD compared with ACS (OR: 1.1 [95% CI: 0.8 to 1.4]; p
0.055).
We further divided our cohort into quartiles of HII to
provide additional support for the correlation between HII and
ACS status (Table 2). Subjects who were in quartile 4 of HII
were more likely to have ACS compared with either controls or
chronic CAD subjects (OR: 1.74 [95% CI: 1.52 to 1.96]), and
this risk persisted after controlling for traditional cardiovascular
risk factors, including HDL cholesterol (OR: 1.23 [95% CI:
1.15 to 1.31]). The same findings were seen in ACS subjects
compared with chronic CAD subjects before and after risk
factor adjustment (OR: 1.91 [95% CI: 1.69 to 2.13]; after
adjustment OR: 1.17 [95% CI: 1.12 to 1.22]). Being in
quartile 2 or 3 of HII did not significantly increase the risk of
having ACS compared with controls or chronic CAD before
or after risk factor adjustment.
Statin treatment and HII. Treatment of healthy subjects
with statin therapy produced expected decreases in total cho-
d ControlsSubjects and Controls
Chronic CAD
(n  51)
Acute Coronary Syndrome
(n  43)
40 (78%)* 31 (72%)*
55.9 7.9† 59.1 11.5‡
29 5.6 29 4.6
28 (55%) 21 (50%)
8 (16%) 9 (20%)
30 (59%) 25 (60%)
4.61 (4.48–4.75) 4.81 (4.62–5.00)
177 37 170 40
44 12 42 8.7
106 30 99 33
0.05 by Pearson chi-square test, compared to control; †p  0.01 by
nificant difference in age between the chronic CAD and ACS subjects
ity lipoprotein; LDL  low-density lipoprotein.ts anCAD
l). *p 
s no siglesterol, triglycerides, C-reactive protein (CRP), and an insig-
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HDL Anti-Inflammatory Property Is Impaired in ACS November 8, 2011:2068–75nificant increase in HDL compared with treatment with a
placebo (Table 3). Additionally, the decrease in cholesterol was
significant and consistent across all statin treatments compared
with baseline. Mean HII did not change in the placebo group,
but there was a trend for decreased HII with individual statin
Figure 3 ORs for CAD According to
HII and Selected Risk Factors
The multivariate logistic regression model was also adjusted for HDL concen-
tration. HII is a significant risk factor for ACS compared with no CAD (A) or
chronic CAD (C), but HII does not confer risk of chronic CAD compared with
controls (B). Bars represent 95% confidence intervals for each odds ratio. *p
 0.01; †p  0.055. HTN  hypertension; LDL  low-density lipoprotein;
other abbreviations as in Figures 1 and 2.
CAD Status According to Quartile of HIITable 2 CAD Status According to Quartile o
Unadjusted OR
Quartile n ACS vs. Control ACS vs. C
1 48 1.00 1
2 48 4.05 0.63 7.50
3 48 1.23 0.34 1.56
4 49 1.74 0.21† 1.91
Odds ratios (ORs) presented are compared to quartile 1 and represen
HDL, and LDL. †p  0.01.
HII  high-density lipoprotein inflammatory index; other abbreviations as itherapy compared with baseline. Taken in aggregate, treatment
with any statin produced a significant decrease in HII com-
pared with placebo (Fig. 4). Interestingly, on bivariate analysis
after log transformation, baseline CRP value correlated signif-
icantly with HII (r  0.25, p  0.02), but this correlation did
ot persist after treatment.
iscussion
n this study, we found that the ability of HDL to prevent
xidation of LDL correlated strongly with ACS status. There
as no association between HII and chronic CAD, but there
as a significant difference between subjects with ACS and
hose with chronic CAD. Furthermore, all of these associa-
ions persisted in a prediction model after adjustment for
raditional cardiovascular disease risk factors including HDL
ass. Our results are the first to our knowledge to demonstrate
ecreased HDL anti-inflammatory capacity in the setting of
CS.
HDL inflammatory index measures one aspect of HDL’s
any purported atheroprotective properties. HDL is a chime-
ic molecule that changes its structure and composition with
mall changes in the environment; even slightly altered diets
an produce different HDL molecules (29). And minor
hanges in microenvironment especially alter the anti-
nflammatory properties of HDL. For example, in chronic
nflammatory conditions such as systemic lupus erythematosis
nd rheumatoid arthritis, atherosclerosis correlates with HII
30). ACS radically changes the circulating environment for
DL, involving both acute inflammation and oxidation, either
s part of its pathogenesis or resulting from the ensuing
amage (31,32).
Chronic CAD subjects did have significantly less HDL-
ediated cholesterol efflux capacity than control subjects in a
imilar population (11); that study did not, however, include
ny ACS subjects. There may be a significant difference in the
unctional assessment of various aspects of the HDL molecule,
concept supported by the lack of association between cho-
esterol efflux capacity and HII within the same subjects in our
tudy (Fig. 1). In our cohort of ACS patients undergoing
ngiography, the acute inflammation that occurred with ACS
ay differ significantly from the chronic inflammation of stable
AD, thus impacting differentially on the HDL inflammatory
ndex.
Adjusted OR for CAD Risk Factors*
CAD ACS vs. Control ACS vs. Chronic CAD
1.00 1.00
1.30 0.21 1.41 0.17
1.09 0.10 1.07 0.08
† 1.23 0.081† 1.17 0.047†
SE. *CAD risk factors included age, smoking, diabetes, hypertension,f HII
hronic
.00
0.70
0.36
0.22
t OR n Table 1.
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November 8, 2011:2068–75 HDL Anti-Inflammatory Property Is Impaired in ACSWe further examined associations between biomarkers of
cardiovascular disease and HII. The AIP correlates with
angiographic CAD, lipoprotein size, and lipoprotein compo-
sition, and in type 2 diabetic patients, reduces after treatment
with pioglitazone (22,28,33–36). There was a clear and direct
association between AIP and HII. AIP tracks with changes in
lipoprotein composition, which in turn is influenced by an
inflammatory milieu. Although we did not see a correlation
between subjects with AIP and ACS compared with chronic
CAD subjects and controls (data not shown), the positive
association between AIP and HII in all subjects suggests that
HDL particle composition, for which AIP is a surrogate, can
influence the anti-inflammatory properties of HDL.
We speculate here a role for HDL in ACS. HDL choles-
terol levels can be lowered in the short term in ACS (37–39).
Additionally, HDL does have many interactions that promote
endothelial and myocardial health. For example, in rats with
induced cardiac ischemia, HDL infusion in the acute setting
enhances myocardial recovery (40). Furthermore, infusion of
apo A1 particles in human subjects results in short-term HDL
increase and immediate restoration of endothelial function as
measured by forearm venous occlusion plethysmography
(41,42). The question remains, then, whether HDL with
reduced anti-inflammatory capacity is a contributor or inno-
cent bystander in acute CAD.
Another finding from our study was that BMI correlated
positively with HII. Others have shown that obstructive sleep
apnea associates with impaired HDL, perhaps because of
increased oxidative stress from periods of hypoxia (43). The
strong association between BMI and obstructive sleep apnea
may explain our findings of increased HII in subjects with
higher BMI. High BMI and high TG levels correlate in
metabolic syndrome, which may involve, not only low HDL,
Figure 4 HII Improves After Statin Therapy
Subjects were treated with placebo, 40-mg pravastatin, 10-mg atorvastatin, or
80-mg atorvastatin daily. Percent change reflects high-density lipoprotein
inflammatory index (HII) in serum samples obtained at the baseline visit and
after 16 weeks of therapy, and error bars represent SEM: 21  13%, p 
0.07 (pravastatin); 10  6%, p  0.16 (atorvastatin 10 mg); 11  8%, p
 0.12 (atorvastatin 80 mg); 14  5%, p  0.03 (any statin). *p  0.03.but more inflammatory HDL as well. Indeed, others haveEf
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HDL Anti-Inflammatory Property Is Impaired in ACS November 8, 2011:2068–75demonstrated smaller, denser, and more dysfunctional HDL in
subjects with metabolic syndrome (44,45). HII can be an
important measure of HDL function in these patients.
Treatment with statins decreased mean HII compared with
placebo. One intriguing possibility is that statins exert an
anti-inflammatory effect through changes in HDL composi-
tion and function (46). However, statin therapy did not affect
cholesterol efflux capacity (11), once again providing evidence
that there may be many pathways to influence different aspects
of HDL function.
Conclusions
HDL’s function as an anti-inflammatory molecule can be
measured reproducibly and reliably using the HII assay applied
to human serum after depletion of apoB lipoproteins. HII is
higher (reflecting reduced anti-inflammatory capacity of
HDL) in the setting of ACS, but not in the setting of chronic
CAD. HDL’s anti-inflammatory function is not correlated
with cholesterol efflux capacity, suggesting that the HII pro-
vides orthogonal information to the efflux assay. Improved
HDL function remains an important therapeutic target, and
our findings may aid in assessing therapies that increase HDL
mass and also improve HDL function, in both chronic disease
states and acute clinical syndromes.
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